Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas

Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas

US Patent 10548896 · Granted Feb 4, 2020

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Bromodomain and extra-terminal protein inhibitor combination therapy2022
Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas2021
Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas2021
Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas2021
Bromodomain and extra-terminal protein inhibitor combination therapy2021
Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas2020
Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas2020
Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas2020
Bromodomain and extra-terminal protein inhibitor combination therapy2020
Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas2020
Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas2020
Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas2020